 This is an outpatient, Phase 2, multicenter, double-blind, placebo-controlled, randomized, parallel-group study assessing the efficacy, safety, and tolerability of MB07811 given orally to subjects with primary hypercholesterolemia for 12 weeks. There will be a 3- to 6-week screeningrun-in period, including washout of any lipid-modifying therapies as needed prior to randomization. Eligible subjects will be randomized 1:1:1:1 to placebo, or 3 different doses of MB07811 for 12 weeks. After the double-blind treatment phase, all randomized subjects will proceed into a 6-week off-drug phase. Assessments include: laboratory tests, adverse events AEs, electrocardiograms ECGs, vitals, and PK samples. 